Amphenol Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 28, 2023, 17:16 ET.
Management's discussion and analysis
As filed, 2,122 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Repurchase of Equity Securities
On April 27, 2021, the Company’s Board of Directors authorized a stock repurchase program under which the Company may purchase up to $2.0 billion of the Company’s Class A Common Stock (“Common Stock”) during the three-year period ending April 27, 2024 (the “2021 Stock Repurchase Program”) in accordance with the requirements of Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). During the three months ended March 31, 2023, the Company repurchased 2.1 million shares of its Common Stock for $166.9 million under the 2021 Stock Repurchase Program. All of the repurchased shares during the first three months of 2023 were retired by the Company. From April 1, 2023 to April 25, 2023, the Company repurchased 0.5 million additional shares of its Common Stock for $39.5 million, and, as of April 26, 2023, the Company has remaining authorization to purchase up to $605.2 million of its Common Stock under the 2021 Stock Repurchase Program. The price and timing of any future purchases will depend on a number of factors, such as levels of cash generation from operations, the volume of stock options exercised by employees, cash requirements for acquisitions, dividends paid, economic and market conditions and the price of the Common Stock.
The table below reflects the Company’s stock repurchases for the three months ended March 31, 2023:
(dollars in millions, except price per share)
| Period | Total Number of Shares Purchased | | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs | |
|---|---|---|---|---|---|---|
| January 1 to January 31, 2023 | 620,795 | $78.55 | 620,795 | $762.8 | | |
| February 1 to February 28, 2023 | 712,457 | | 80.00 | 712,457 | 705.8 | |
| March 1 to March 31, 2023 | 784,027 | | 77.98 | 784,027 | $644.7 | |
| Total | 2,117,279 | $78.83 | 2,117,279 | | |
Market risk
As filed, 3,171 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(amounts in millions)
The Company, in the normal course of doing business, is exposed to a variety of risks, including market risks associated with foreign currency exchange rates and changes in interest rates. The Company does not have any significant concentration with any one counterparty. There has been no material change in the Company’s assessment of its sensitivity to foreign currency exchange rate risk since its presentation set forth in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk in its 2022 Annual Report. From time to time, the Company may borrow under the Revolving Credit Facility, Commercial Paper Programs, and the two-year, $750.0 unsecured delayed draw term loan credit agreement (the “2022 Term Loan”). Any borrowings under the Euro Commercial Paper Program and Revolving Credit Facility, in addition to the outstanding borrowings under the Company’s Euro Notes, as discussed in Note 4 of the Notes to Condensed Consolidated Financial Statements, are and may continue to be denominated in foreign currencies, and there can be no assurance that the Company can successfully manage changes in exchange rates, including in the event of a significant and sudden decline in the value of any of the foreign currencies in which such borrowings are made. In addition, any borrowings under the Revolving Credit Facility bear interest at rates that fluctuate with a spread that varies, based on the Company’s debt rating, over certain currency-specific benchmark rates, which benchmark rates in the case of U.S. dollar borrowings are either the base rate or the adjusted term Secured Overnight Financing Rate (“SOFR”). Similarly, any borrowings under the 2022 Term Loan entered into by the Company in April of 2022, bear interest at rates that fluctuate with a spread that varies, based on the Company’s debt rating, over either the base rate or the adjusted term SOFR. Any borrowings under the Commercial Paper Programs are subject to floating interest rates. Therefore, when the Company borrows under these debt instruments, the Company is exposed to market risk related to changes in interest rates. As of March 31, 2023, outstanding borrowings under the U.S. Commercial Paper Program were at a weighted average floating interest rate of 5.29%, while there were no outstanding borrowings under the Revolving Credit Facility, 2022 Term Loan and Euro Commercial Paper Program. As a result of recent increases in the federal funds rate by the U.S. Federal Reserve beginning in March 2022 through the first quarter of 2023, the floating interest rates related to our U.S. Commercial Paper Program have increased substantially. To the extent that the interest rates related to our floating rate debt continue to increase, interest expense will increase for the remainder of 2023. Although the Company does not expect changes in interest rates to have a material effect on income or cash flows for the remainder of 2023, primarily due to our current expected limited reliance on borrowings tied to floating rates of interest, there can be no assurance that interest rates will not change significantly from current levels.
Controls and procedures
As filed, 1,503 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. These disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this report.
Changes in Internal Control Over Financial Reporting
There has been no change in our internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 190 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the Company’s risk factors as disclosed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $2.97bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $2.03bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $943.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $346.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $591.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $35.9m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $117.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $439.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 619,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $532.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $97.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-01-01 to 2023-03-31 | $124.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $166.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $1.39bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $6.39bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $15.38bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $2.43bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $8.00bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $7.31bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-007328. Last ingested by Listed: Nov 3, 2026, 18:42 ET. Listed shows no prices and gives no investment advice.